Baidu
map

神经科指南

订阅

MedSci主页 / 所有栏目 / 神经科指南

2018 ECTRIMS/EAN指南：多发性硬化患者的药物治疗

2018-01-11 欧洲神经病学研究院 European Journal of Neurology.2018.

多发性硬化药物治疗

2018年1月，欧洲多发性硬化治疗和研究委员会(ECTRIMS)联合欧洲神经病学研究院(EAN)共同发布了多发性硬化患者的药物治疗指南。多发性硬化是中枢神经系统一种复杂的病变。本文主要针对该病的药物治疗提供指导建议，疾病修饰治疗药物的有效性，治疗反应监测，治疗策略，长期治疗以及特殊情况的治疗等。

中文标题：

2018 ECTRIMS/EAN指南：多发性硬化患者的药物治疗

英文标题：

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

发布机构：

欧洲神经病学研究院

发布日期：

2018-01-11

简要介绍：

2018年1月，欧洲多发性硬化治疗和研究委员会(ECTRIMS)联合欧洲神经病学研究院(EAN)共同发布了多发性硬化患者的药物治疗指南。多发性硬化是中枢神经系统一种复杂的病变。本文主要针对该病的药物治疗提供指导建议，疾病修饰治疗药物的有效性，治疗反应监测，治疗策略，长期治疗以及特殊情况的治疗等。

 

拓展指南：与多发性硬化相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 ECTRIMS/EAN指南：多发性硬化患者的药物治疗)] GetToolGuiderByIdResponse(projectId=1, id=0b98c1c0015a6e08, title=2018 ECTRIMS/EAN指南：多发性硬化患者的药物治疗, enTitle=ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis, guiderFrom=European Journal of Neurology.2018., authorId=null, author=, summary=2018年1月，欧洲多发性硬化治疗和研究委员会(ECTRIMS)联合欧洲神经病学研究院(EAN)共同发布了多发性硬化患者的药物治疗指南。多发性硬化是中枢神经系统一种复杂的病变。本文主要针对该病的药物治疗提供指导建议，疾病修饰治疗药物的有效性，治疗反应监测，治疗策略，长期治疗以及特殊情况的治疗等。 , cover=, journalId=null, articlesId=null, associationId=1237, associationName=欧洲神经病学研究院, associationIntro=, copyright=0, guiderPublishedTime=Thu Jan 11 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年1月，欧洲多发性硬化治疗和研究委员会(ECTRIMS)联合欧洲神经病学研究院(EAN)共同发布了多发性硬化患者的药物治疗指南。多发性硬化是中枢神经系统一种复杂的病变。本文主要针对该病的药物治疗提供指导建议，疾病修饰治疗药物的有效性，治疗反应监测，治疗策略，长期治疗以及特殊情况的治疗等。 </P> <P> </P>拓展指南：<strong>与<font color=red>多发性硬化</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=3b1b51c0015a20c5" title="多发性硬化的诊断：2017版McDonald标准" target=_blank>多发性硬化的诊断：2017版McDonald标准</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=2f90c1c001ae7130" title="多发性硬化影像诊断标准：中国专家共识" target=_blank>多发性硬化影像诊断标准：中国专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=340e21c001a56043" title="2015 加拿大共识建议：MRI检查在优化多发性硬化治疗中的作用" target=_blank>2015 加拿大共识建议：MRI检查在优化多发性硬化治疗中的作用</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=f0e981c00133635c" title="2016 欧洲多发性硬化专家建议：阿仑单抗的临床应用" target=_blank>2016 欧洲多发性硬化专家建议：阿仑单抗的临床应用</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=ba9441c001222e9b" title="2016 CMSC修订建议：标准化MRI协议和多发性硬化的诊断与随访" target=_blank>2016 CMSC修订建议：标准化MRI协议和多发性硬化的诊断与随访</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E5%A4%9A%E5%8F%91%E6%80%A7%E7%A1%AC%E5%8C%96" target=_blank>有关多发性硬化更多指南</a></ul>, tagList=[TagDto(tagId=3389, tagName=多发性硬化), TagDto(tagId=1113, tagName=药物治疗)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6496, appHits=230, showAppHits=0, pcHits=3929, showPcHits=3089, likes=152, shares=9, comments=6, approvalStatus=1, publishedTime=Wed Jan 24 11:51:33 CST 2018, publishedTimeString=2018-01-11, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Jan 24 11:51:33 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:33:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 ECTRIMS/EAN指南：多发性硬化患者的药物治疗)])
2018 ECTRIMS/EAN指南：多发性硬化患者的药物治疗
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=282535, encodeId=8ed028253504, content=谢谢分享.谢谢.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jan 27 12:23:14 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281598, encodeId=bced28159844, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:49:14 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281580, encodeId=7382281580f6, content=学习学习.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:06:09 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281560, encodeId=811a2815604b, content=谢谢分享. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:51 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281559, encodeId=02ff281559f3, content=继续关注. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:42 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-27 虈亣靌

    谢谢分享.谢谢.学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=282535, encodeId=8ed028253504, content=谢谢分享.谢谢.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jan 27 12:23:14 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281598, encodeId=bced28159844, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:49:14 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281580, encodeId=7382281580f6, content=学习学习.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:06:09 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281560, encodeId=811a2815604b, content=谢谢分享. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:51 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281559, encodeId=02ff281559f3, content=继续关注. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:42 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-24 131****1460

    学习了受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=282535, encodeId=8ed028253504, content=谢谢分享.谢谢.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jan 27 12:23:14 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281598, encodeId=bced28159844, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:49:14 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281580, encodeId=7382281580f6, content=学习学习.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:06:09 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281560, encodeId=811a2815604b, content=谢谢分享. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:51 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281559, encodeId=02ff281559f3, content=继续关注. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:42 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-24 1dd8c52fm63(暂无匿称)

    学习学习.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=282535, encodeId=8ed028253504, content=谢谢分享.谢谢.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jan 27 12:23:14 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281598, encodeId=bced28159844, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:49:14 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281580, encodeId=7382281580f6, content=学习学习.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:06:09 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281560, encodeId=811a2815604b, content=谢谢分享. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:51 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281559, encodeId=02ff281559f3, content=继续关注. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:42 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-24 doctorJiangchao

    谢谢分享.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=282535, encodeId=8ed028253504, content=谢谢分享.谢谢.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jan 27 12:23:14 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281598, encodeId=bced28159844, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:49:14 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281580, encodeId=7382281580f6, content=学习学习.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:06:09 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281560, encodeId=811a2815604b, content=谢谢分享. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:51 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281559, encodeId=02ff281559f3, content=继续关注. , beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jan 24 12:28:42 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-24 doctorJiangchao

    继续关注.

    0

相关指南

多发性硬化影像诊断标准：中国专家共识

中国影像科相关专家小组 · 2017-02-20

多发性硬化诊断和治疗中国专家共识(2014版)

中华医学会神经病学分会神经免疫学组 · 2016-04-21

2014 NICE临床指南：在初级和二级医疗中多发性硬化的管理（CG186）

暂未更新 · 2014-10-15

2014 多发性硬化疾病修饰疗法专家共识

国外神经内科相关专家小组（统称） · 2014-07-01

多发性硬化临床病程的定义（2013版）

国际多发性硬化专家组(International Panel of MS) · 2014-05-21

2014AAN多发性硬化补充及替代药物治疗指南

美国神经病学学会(AAN,American Academy of Neurology) · 2014-03-24

Baidu
map
Baidu
map
Baidu
map